ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer (ADELE): a randomised phase 2 trial

The ADELE clinical trial seeks to improve outcomes for people with high-risk endometrial cancer, who have a significant risk of relapse after standard post-operative treatment with chemotherapy & radiotherapy. It is hoped that this study may improve relapse rates in high-risk endometrial cancer by adding Tislelizumab immunotherapy to standard treatment.

Primary Sponsor

Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

135

Expected Date of Accrual

March 2025

Trial Chairperson

Professor Linda Mileshkin, Peter MacCallum Cancer Centre, VIC, Australia

Dr Yeh Chen Lee, NHMRC Clinical Trials Centre & Prince of Wales Hospital

Trial Contact

qa@trog.com.au

Related Post

Prof Paul Keall, Image X Director and VITaL trial chief investigator
15 May, 2025

Grant for trial of new imaging technique to reduce radiation therapy side effects in lung cancer

LATEST NEWS: 15 May 2025 A novel imaging modality

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is